Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.55 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 8/20 | 0.46 |
| ▸ | MAOA | P21397 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 3/20 | 0.42 |
| ▸ | PPARD | Q03181 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | SLC8A1 | P32418 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10635827 | 0.88 | ITGB3 (0.60) | ITGB3ITGA2BCYP4F2CYP4A11PPARA | |
| Hydrochloric Acid SCHEMBL6953799 | 0.84 | ITGB3 (0.64) | ITGB3ITGA2BRAB9ACYP4F2CYP4A11 | |
| Hydrochloric Acid SCHEMBL6953730 | 0.84 | ITGB3 (0.77) | ITGB3ITGA2B | |
| Hydrochloric Acid SCHEMBL6953736 | 0.83 | ITGB3 (0.55) | ITGB3ITGA2BMAOBRAB9ACYP4F2 | |
| SCHEMBL6959354 | 0.80 | ITGB3 (0.43) | ITGB3ITGA2BCYP4F2CYP4A11PPARA | |
| SCHEMBL10635876 | 0.80 | HTR6 (0.61) | ITGB3ITGA2BPPARAPPARDPPARG | |
| SCHEMBL7302032 | 0.80 | MAOB (0.46) | MAOBMAOARAB9AACHEKCNH2 | |
| SCHEMBL6949063 | 0.79 | ITGB3 (0.56) | ITGB3ITGA2BRAB9A | |
| SCHEMBL6948869 | 0.78 | ITGB3 (0.56) | ITGB3ITGA2BRAB9ACYP4F2CYP4A11 | |
| SCHEMBL6954907 | 0.78 | CYP4F2 (0.48) | CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030130342-A1 | Glycoprotein llb/llla antagonists | FISHER MATTHEW J (US) | 2003-07-10 | — | — | US | disclosed |
| EP-0804431-B9 | GLYCOPROTEIN IIb/IIIa ANTAGONISTS | LILLY CO ELI (US) | 2003-01-02 | — | — | EP | disclosed |
| US-6448269-B1 | SUCH AS 6-(N-(4-(AMINOIMINOMETHYL)BENZOYL)AMINO)-3,4-DIHYDRO-4,4-DIMETHYL-2H-1 -BENZOPYRAN-2-YL)ACETIC ACID; INHIBITING PLATELET AGGREGATION OR FIBRINOGEN BINDING OR PREVENTING THROMBOSIS | ELI LILLY AND COMPANY | 2002-09-10 | — | — | US | disclosed |
| EP-0804431-B1 | GLYCOPROTEIN IIb/IIIa ANTAGONISTS | LILLY CO ELI (US) | 2002-07-24 | — | — | EP | disclosed |
| US-6020362-A | ANTICOAGULANTS | ELI LILLY AND COMPANY (US) | 2000-02-01 | — | — | US | disclosed |
| US-5731324-A | Glycoprotein IIb/IIIa antagonists | ELI LILLY AND COMPANY (US) | 1998-03-24 | — | — | US | disclosed |
| WO-1996022288-A1 | GLYCOPROTEIN IIb/IIIa ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130342-A1 | Glycoprotein llb/llla antagonists | SELL, SELPLG, LY96 | ITGB3 653/4885ITGA2B 294/4885MAOB 2042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.